The Milton and Carroll Petrie Department of Urology at Mount Sinai is transforming prostate cancer treatment and expanding our knowledge about the causes of and cures for the disease.
Our robotic prostate surgery program is led by Ashutosh (Ash) K. Tewari, MBBS, MCh, Chairman of the Department of Urology and one of the world's foremost researchers and surgeons in the field of prostate cancer. A pioneer of Da Vinci robotic surgery for prostate cancer, Dr. Tewari has performed more than 5,500 robotic prostatectomies (surgery to remove the entire prostate), making him one of the most skilled an experienced robotic surgeons in the world - expertise that is especially important if you are considering robotic prostatectomy where successful surgery depends more on the skill and experience of the surgeon than on the technology. Dr. Tewari performs all aspects of surgery himself and ensures that all patients receive the best possible care. Importantly, our Precision Urology (TM) approach involves integration of clinical, genomic, molecular and pathological imaging data for diagnosis and treatment decision-making so that men with prostate cancer can be assured of our commitment to diagnosis and achieving excellent outcomes while minimizing the side effects of treatment. Dr. Tewari also has one of the largest active surveillance (wait to treat) programs so men at lower risk for aggressive cancer can be monitored until intervention is warranted.
We offer all treatment modalities for prostate cancer, including focal and targeted therapy and collaborate very closely with radiation therapy and medical oncology experts to provide every currently available treatment. In collaboration with the Tisch Cancer Center, we oversee clinical trials that provide cutting edge care in the hands of our physicians.